索安非托
外观
![]() | |
臨床資料 | |
---|---|
商品名 | Sunosi |
其他名稱 | SKL-N05, ADX-N05, ARL-N05, YKP10A, R228060, and JZP-110; (R)-2-amino-3-phenylpropylcarbamate hydrochloride |
AHFS/Drugs.com | Monograph |
MedlinePlus | a619040 |
核准狀況 | |
给药途径 | By mouth |
藥物類別 | Norepinephrine–dopamine reuptake inhibitors |
ATC碼 | |
法律規範狀態 | |
法律規範 |
|
藥物動力學數據 | |
生物利用度 | ~95%[2] |
血漿蛋白結合率 | 13.3–19.4%[2] |
药物代谢 | Minimal[2] |
生物半衰期 | ~7.1 hours[2] |
排泄途徑 | Urine (95% unchanged) |
识别信息 | |
| |
CAS号 | 178429-62-4 |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
化学信息 | |
化学式 | C10H14N2O2 |
摩尔质量 | 194.23 g·mol−1 |
3D模型(JSmol) | |
| |
|
索安非托(英語:Solriamfetol,商品名有:Sunosi),也叫索利氨酯,是一种有机化合物,分子式C10H14N2O2,可用于治疗睡眠呼吸暂停和發作性嗜睡病[2][3][4]。
参考文献
[编辑]- ^ Summary Basis of Decision (SBD) for Sunosi. Health Canada. 23 October 2014 [29 May 2022]. (原始内容存档于2023-03-06).
- ^ 2.0 2.1 2.2 2.3 2.4 2.5 Sunosi – solriamfetol tablet, film coated. DailyMed. 16 October 2019 [24 November 2019]. (原始内容存档于2020-08-07).
- ^ Powell J, Piszczatoski C, Garland S. Solriamfetol for Excessive Sleepiness in Narcolepsy and Obstructive Sleep Apnea. Ann Pharmacother. October 2020, 54 (10): 1016–1020. PMID 32270686. S2CID 215605290. doi:10.1177/1060028020915537.
- ^ Abad VC, Guilleminault C. Solriamfetol for the treatment of daytime sleepiness in obstructive sleep apnea. Expert Rev Respir Med. December 2018, 12 (12): 1007–1019. PMID 30365900. S2CID 53106520. doi:10.1080/17476348.2018.1541742.
外部链接
[编辑]- Solriamfetol. Drug Information Portal. U.S. National Library of Medicine. [2023-10-29]. (原始内容存档于2022-12-05).
- Solriamfetol hydrochloride. Drug Information Portal. U.S. National Library of Medicine. [2023-10-29]. (原始内容存档于2021-08-29).